Drugs / TdaP2gen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07621341 | May 2026 → Dec 2029 expected | diphtheria, pertussis, tetanus | Chiang Mai University | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-06-19 | BioNet-Asia Co., Ltd. | Results Avidity of pertussis toxin antibodies following vaccination with genetically versus chemically detoxified pertussis toxin-containing vaccines during pregnancy bionet-asia.com ↗
Avidity was comparable to Tdap8chem after vaccination with the low-dose PTgen formulations (ap1gen, Tdap1gen or Tdap2gen). |
| 2024-01-12 | BioNet-Asia Co., Ltd. | Results Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines bionet-asia.com ↗
No difference in PTNA titers at birth was observed between all groups nor between time of vaccination. |
| 2023-12-12 | BioNet-Asia Co., Ltd. | Results Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines bionet-asia.com ↗
At 2 months, PT GMC ratio to Tdap8chem (98.75% CI) was significantly higher for TdaP5gen (2.6 [1.7–4.0]) and comparable for other recombinant vaccines. |
| 2023-06-22 | BioNet-Asia Co., Ltd. | Results A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women bionet-asia.com ↗
Combined with data from 250 non-pregnant women, all study vaccines containing PTgen were non-inferior to comparator vaccine (Tdap8chem). |
| 2022-04-05 | BioNet-Asia Co., Ltd. | Results A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age bionet-asia.com ↗
Post-vaccination PT-IgG seroresponse rates were 92% (95% CI 81–98) for ap1gen, 88% (95% CI 76–95) for Tdap1gen, 80% (95% CI 66–90) for Tdap2gen, 94% (95% CI 83–99) for TdaP5gen, and 78% (95% CI 64–88) for Tdap8chem. |
All press releases naming this drug 5 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TdaP2gen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07621341 ↗ |
| Modality | Vaccine | “recombinant acellular pertussis vaccine” NCT07621341 ↗ |